A Comprehensive Review on Sodium Glucose Co-Transporter-2 Inhibitors-Empagliflozin

A Comprehensive Review on Sodium Glucose Co-Transporter-2 Inhibitors-Empagliflozin Sanjaana Arun School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advance Studies (VISTAS) Chennai, Tamil Nadu, India. Praveen D Research Scholar, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advance Studies (VISTAS) Chennai, Tamil Nadu, India. Ranadheer Chowdary P Research Scholar, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advance Studies (VISTAS) Chennai, Tamil Nadu, India. Vijey Aanandhi M Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advance Studies (VISTAS) Chennai, Tamil Nadu, India.

Diabetes is one of the most common global illness affecting millions of people in the world. SGLT2 is newly classified anti-diabetic drug, it is highly selective novel approach for type –II diabetes patients because it as low affinity to plasma proteins and high capacity transport of glucose protein compared to SGLT1. Empagliflozin is highly selective for SGLT2, which is sold under the brand name of Jardiance it is mainly recommended for type II DM. The studies have proven that empagliflozin shows both Cardio protective and Reno protective effects and well established for the management of weight loss in diabetes mellitus. Pharmacokinetic studies are well achieved and shown no major drug interactions and less side effects. SGLT2 inhibitors have given novel approach about orally administered drug and more or less this can benefit the patients for easy life style without leading to further complications.
5 30 2022 5 30 2022 2376 2380 10.52711/0974-360X.2022.00395 https://rjptonline.org/AbstractView.aspx?PID=2022-15-5-77 10.1080/14740338.2018.1497159 Scheen, A. (2018). The safety of empagliflozin plus metformin for the treatment of type 2 diabetes. Expert Opinion on Drug Safety, 17(8), pp.837-848. 10.1002/ejhf.1328 Pabel, S., Wagner, S., Bollenberg, H., Bengel, P., Kovács, Á., Schach, C., Tirilomis, P., Mustroph, J., Renner, A., Gummert, J., Fischer, T., Van Linthout, S., Tschöpe, C., Streckfuss‐Bömeke, K., Hasenfuss, G., Maier, L., Hamdani, N. and Sossalla, S. (2018). Empagliflozin directly improves diastolic function in human heart failure. European Journal of Heart Failure, 20(12), pp.1690-1700. 10.1136/bmj.l4772 Pasternak, B., Ueda, P., Eliasson, B., Svensson, A., Franzén, S., Gudbjörnsdottir, S., Hveem, K., Jonasson, C., Wintzell, V., Melbye, M. and Svanström, H. (2019). Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. BMJ, p.l4772. 10.1016/j.dsx.2019.04.035 Chawla, G. and Chaudhary, K. (2019). A complete review of empagliflozin: Most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 13(3), pp.2001-2008. 10.1002/edm2.16 DeFronzo, R., Ferrannini, E., Schernthaner, G., Hantel, S., Elsasser, U., Lee, C., Hach, T. and Lund, S. (2018). Slope of change in HbA1c from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes. Endocrinology, Diabetes & Metabolism, 1(2), p.e00016. 10.1038/s41440-019-0326-3 Kim, S., Jo, C. and Kim, G. (2019). Effects of empagliflozin on nondiabetic salt-sensitive hypertension in uninephrectomized rats. Hypertension Research, 42(12), pp.1905-1915. 10.1007/s40265-018-0937-z Frampton, J. (2018). Empagliflozin: A Review in Type 2 Diabetes. Drugs, 78(10), pp.1037-1048. 10.18773/austprescr.2014.005 Thynne, T. and Doogue, M. (2013). Experimental and Clinical Pharmacology: Sodium-glucose co-transporter inhibitors: Mechanisms of action. Australian Prescriber, 37(1), pp.14-16. 10.1038/s41440-019-0326-3 Kim, S., Jo, C. and Kim, G. (2019). Effects of empagliflozin on nondiabetic salt-sensitive hypertension in uninephrectomized rats. Hypertension Research, 42(12), pp.1905-1915. 10.32474/ado.2018.01.000111 Papanas, N. (2018). Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes. Archives of Diabetes & Obesity, 1(3). 10.2337/ds16-0030 Zurek, A., Yendapally, R. and Urteaga, E. (2017). A Review of the Efficacy and Safety of Sodium–Glucose Cotransporter 2 Inhibitors: A Focus on Diabetic Ketoacidosis. Diabetes Spectrum, 30(2), pp.137-142. 10.1186/s12933-018-0750-8 Aroor, A., Das, N., Carpenter, A., Habibi, J., Jia, G., Ramirez-Perez, F., Martinez-Lemus, L., Manrique-Acevedo, C., Hayden, M., Duta, C., Nistala, R., Mayoux, E., Padilla, J., Chandrasekar, B. and DeMarco, V. (2018). Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury. Cardiovascular Diabetology, 17(1).